Cargando…

A Receptor Tyrosine Kinase Inhibitor Sensitivity Prediction Model Identifies AXL Dependency in Leukemia

Despite incredible progress in cancer treatment, therapy resistance remains the leading limiting factor for long-term survival. During drug treatment, several genes are transcriptionally upregulated to mediate drug tolerance. Using highly variable genes and pharmacogenomic data for acute myeloid leu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nasimian, Ahmad, Al Ashiri, Lina, Ahmed, Mehreen, Duan, Hongzhi, Zhang, Xiaoyue, Rönnstrand, Lars, Kazi, Julhash U.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9959897/ https://www.ncbi.nlm.nih.gov/pubmed/36835239 http://dx.doi.org/10.3390/ijms24043830

Ejemplares similares

Venetoclax-Resistant T-ALL Cells Display Distinct Cancer Stem Cell Signatures and Enrichment of Cytokine Signaling
por: Shah, Kinjal, et al.
Publicado: (2023)

A deep tabular data learning model predicting cisplatin sensitivity identifies BCL2L1 dependency in cancer
por: Nasimian, Ahmad, et al.
Publicado: (2023)

Src-Like Adaptor Protein (SLAP) Binds to the Receptor Tyrosine Kinase Flt3 and Modulates Receptor Stability and Downstream Signaling
por: Kazi, Julhash U., et al.
Publicado: (2012)

Understanding the Role of Activation Loop Mutants in Drug Efficacy for FLT3-ITD
por: Kazi, Julhash U., et al.
Publicado: (2023)

The Src family kinase LCK cooperates with oncogenic FLT3/ITD in cellular transformation
por: Marhäll, Alissa, et al.
Publicado: (2017)

FYN expression potentiates FLT3-ITD induced STAT5 signaling in acute myeloid leukemia
por: Chougule, Rohit A., et al.
Publicado: (2016)

The Aurora kinase/β-catenin axis contributes to dexamethasone resistance in leukemia
por: Shah, Kinjal, et al.
Publicado: (2021)

PLK1 as a cooperating partner for BCL2-mediated antiapoptotic program in leukemia
por: Shah, Kinjal, et al.
Publicado: (2023)

The ALK inhibitor AZD3463 effectively inhibits growth of sorafenib-resistant acute myeloid leukemia
por: Moharram, Sausan A., et al.
Publicado: (2019)

Correction: The ALK inhibitor AZD3463 effectively inhibits growth of sorafenib-resistant acute myeloid leukemia
por: Moharram, Sausan A., et al.
Publicado: (2019)

Glucocorticoid-resistant B cell acute lymphoblastic leukemia displays receptor tyrosine kinase activation
por: Chougule, Rohit A., et al.
Publicado: (2019)

SRC-like adaptor protein 2 (SLAP2) is a negative regulator of KIT-D816V-mediated oncogenic transformation
por: Rupar, Kaja, et al.
Publicado: (2018)

Metallopeptidase inhibitor 1 (TIMP‐1) promotes receptor tyrosine kinase c‐Kit signaling in colorectal cancer
por: Nordgaard, Cathrine, et al.
Publicado: (2019)

The Receptor Tyrosine Kinase AXL in Cancer Progression
por: Rankin, Erinn B., et al.
Publicado: (2016)

AXL receptor tyrosine kinase: a possible therapeutic target in acute promyelocytic leukemia
por: Fatima, Mariam, et al.
Publicado: (2021)

Chronic lymphocytic leukemia cells from ibrutinib treated patients are sensitive to Axl receptor tyrosine kinase inhibitor therapy
por: Sinha, Sutapa, et al.
Publicado: (2018)

Tyrosine 842 in the activation loop is required for full transformation by the oncogenic mutant FLT3-ITD
por: Kazi, Julhash U., et al.
Publicado: (2017)

BEX1 acts as a tumor suppressor in acute myeloid leukemia
por: Lindblad, Oscar, et al.
Publicado: (2015)

Quantitative Tyrosine Phosphoproteome Profiling of AXL Receptor Tyrosine Kinase Signaling Network
por: Wu, Xinyan, et al.
Publicado: (2021)

AXL receptor tyrosine kinase as a therapeutic target in NSCLC
por: Okimoto, Ross A, et al.
Publicado: (2015)

Implications of the Receptor Tyrosine Kinase Axl in Gastric Cancer Progression
por: He, Lirui, et al.
Publicado: (2020)

Axl receptor tyrosine kinase is a regulator of apolipoprotein E
por: Zhao, Wenchen, et al.
Publicado: (2020)

Predicting the Specificity- Determining Positions of Receptor Tyrosine Kinase Axl
por: Karakulak, Tülay, et al.
Publicado: (2021)

Expression of GADS enhances FLT3-induced mitogenic signaling
por: Chougule, Rohit A., et al.
Publicado: (2016)

P479: TREATMENT IS SHAPING CLONAL EVOLUTION AND RESISTANCE PATTERNS IN MURINE KMT2A-REARRANGED LEUKEMIA WITH SUBCLONAL FLT3N676K
por: Falqués-Costa, Ton, et al.
Publicado: (2023)

Implication of the Receptor Tyrosine Kinase AXL in Head and Neck Cancer Progression
por: von Mässenhausen, Anne, et al.
Publicado: (2016)

AXL receptor tyrosine kinase is required for T cell priming and antiviral immunity
por: Schmid, Edward T, et al.
Publicado: (2016)

AXL and MET receptor tyrosine kinases are essential for lung cancer metastasis
por: Choi, Yun Jung, et al.
Publicado: (2019)

The receptor tyrosine kinase AXL promotes migration and invasion in colorectal cancer
por: Uribe, Diana J., et al.
Publicado: (2017)

The Axl receptor tyrosine kinase is a discriminator of macrophage function in the inflamed lung
por: Fujimori, T, et al.
Publicado: (2015)

Molecular analysis of alternative transcripts of equine AXL receptor tyrosine kinase gene
por: Park, Jeong-Woong, et al.
Publicado: (2017)

Expression of AXL receptor tyrosine kinase relates to monocyte dysfunction and severity of cirrhosis
por: Brenig, Robert, et al.
Publicado: (2019)

AXL receptor tyrosine kinase modulates gonadotropin-releasing hormone receptor signaling
por: Mohammadzadeh, Pardis, et al.
Publicado: (2023)

Comparative analysis of human and bovine protein kinases reveals unique relationship and functional diversity
por: Kabir, Nuzhat N., et al.
Publicado: (2011)

Src-like adaptor protein 2 (SLAP2) binds to and inhibits FLT3 signaling
por: Moharram, Sausan A., et al.
Publicado: (2016)

Targeting AXL kinase sensitizes leukemic stem and progenitor cells to venetoclax treatment in acute myeloid leukemia
por: Niu, Xiaojia, et al.
Publicado: (2021)

Overexpression of the Axl tyrosine kinase receptor in cutaneous SCC-derived cell lines and tumours
por: Green, J, et al.
Publicado: (2006)

Gas6 and the Receptor Tyrosine Kinase Axl in Clear Cell Renal Cell Carcinoma
por: Gustafsson, Anna, et al.
Publicado: (2009)

Axl receptor tyrosine kinase is a potential therapeutic target in renal cell carcinoma
por: Yu, H, et al.
Publicado: (2015)

Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells
por: Bansal, Nitu, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_odpv38mrrr2poqj5vqfoa20gbi